Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Sep;40(9):2062–2066. doi: 10.1128/aac.40.9.2062

In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae.

P Chavanet 1, N Peyrard 1, A Pechinot 1, M Buisson 1, M Duong 1, C Neuwirth 1, A Kazmierczak 1, H Portier 1
PMCID: PMC163473  PMID: 8878581

Abstract

Using a clinical pneumococcal strain for which MICs were 4, 2, and 32 mg/liter for penicillin, amoxicillin, and fosfomycin, respectively, we studied the efficacies of these antibiotics alone and their combinations in the treatment of prolonged (48-h) experimental fibrin clot infection in rabbits. Treatments were as follows: amoxicillin IV at 20 mg/kg of body weight in one dose (Amo20), 50 mg/kg in one dose (Amo50), or two doses 6 h apart (Amo20 x 2 and Amo50 x 2); fosfomycin IV at a fixed dose of 50 mg/kg in one dose (Fos50) or two divided doses 6 h apart (Fos50 x 2); or the combinations of amoxicillin and fosfomycin with the same schedules. Maximum concentrations in clots were 2.03 +/- 1.02 and 2.13 +/- 0.33 mg/liter for Amo20 regimens, 3.7 +/- 1.9 and 4 +/- 1.3 mg/liter for Amo50 regimens, and 24 +/- 7 and 40 +/- 8 mg/liter for fosfomycin regimens, respectively. The mean half-lives of elimination from clots were between 2 and 3 h for amoxicillin regimens and between 5 and 7 h for fosfomycin. We observed the highest bacterial reductions (log10 CFU/gram) for Amo50 in two divided doses with or without fosfomycin. A significantly higher bacterial reduction than that with each monotherapy was observed when Amo20 was combined with fosfomycin in either one dose or two doses 6 h apart (0.16 +/- 0.8 and 1.64 +/- 1.6 log10 CFU/g for Amo20 in one and two doses, respectively, and 0.93 +/- 0.81 and 0.61 +/- 0.56 log10 CFU/g for fosfomycin in one and two doses, respectively, versus 3.46 +/- 1.26 and 3.16 +/- 1.31 log10 CFU/g for Amo20 plus fosfomycin in one and two doses, respectively [P < 0.001]). A time-dependent effect was observed with amoxicillin regimens. The time of regrowth was significantly delayed when amoxicillin was combined with fosfomycin. By using a multivariate analysis, we demonstrated that the most important parameter correlated to efficacy of the combination amoxicillin-fosfomycin was the length of the period during which the concentration of amoxicillin remained above the MIC. We demonstrated that the in vivo efficacy of the combination of amoxicillin and fosfomycin gave higher antibacterial effect than each monotherapy.

Full Text

The Full Text of this article is available as a PDF (251.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  2. Appelbaum P. C. New prospects for antibacterial agents against multidrug-resistant pneumococci. Microb Drug Resist. 1995 Spring;1(1):43–48. doi: 10.1089/mdr.1995.1.43. [DOI] [PubMed] [Google Scholar]
  3. Barakett V., Lesage D., Delisle F., Burghoffer B., Richard G., Vergez P., Petit J. C. Synergy of cefotaxime and fosfomycin against penicillin-resistant pneumococci. J Antimicrob Chemother. 1993 Jan;31(1):105–109. doi: 10.1093/jac/31.1.105. [DOI] [PubMed] [Google Scholar]
  4. Barakett V., Lesage D., Delisle F., Guidet B., Burghoffer B., Richard G., Offenstadt G., Vergez P., Petit J. C. Activité bactériostatique et cinétique de bactéricidie de huit antibiotiques vis-à-vis de sept souches de pneumocoques résistants a la pénicilline G. Pathol Biol (Paris) 1992 May;40(5):483–491. [PubMed] [Google Scholar]
  5. Barry B., Muffat-Joly M., Gehanno P., Pocidalo J. J. Effect of increased dosages of amoxicillin in treatment of experimental middle ear otitis due to penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 1993 Aug;37(8):1599–1603. doi: 10.1128/aac.37.8.1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bergeron M. G., Robert J., Beauchamp D. Pharmacodynamics of antibiotics in fibrin clots. J Antimicrob Chemother. 1993 May;31 (Suppl 500):113–136. doi: 10.1093/jac/31.suppl_d.113. [DOI] [PubMed] [Google Scholar]
  7. Bradley J. S., Connor J. D. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J. 1991 Nov;10(11):871–873. [PubMed] [Google Scholar]
  8. Cassinat B., Nicolas M. H. Comparison of antibiotic combinations against penicillin-resistant pneumococci. J Antimicrob Chemother. 1994 Nov;34(5):785–790. doi: 10.1093/jac/34.5.785. [DOI] [PubMed] [Google Scholar]
  9. Catalán M. J., Fernández J. M., Vazquez A., Varela de Seijas E., Suárez A., Bernaldo de Quirós J. C. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin Infect Dis. 1994 May;18(5):766–769. doi: 10.1093/clinids/18.5.766. [DOI] [PubMed] [Google Scholar]
  10. Chavanet P., Beloeil H., Pechinot A., Duigou F., Buisson J. C., Duong M., Neuwirth C., Kazmierczak A., Portier H. In vivo activity and pharmacodynamics of cefotaxime or ceftriaxone in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 1995 Aug;39(8):1736–1743. doi: 10.1128/aac.39.8.1736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Coffey T. J., Daniels M., McDougal L. K., Dowson C. G., Tenover F. C., Spratt B. G. Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resistance to expanded-spectrum cephalosporins. Antimicrob Agents Chemother. 1995 Jun;39(6):1306–1313. doi: 10.1128/aac.39.6.1306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Figueiredo A. M., Connor J. D., Severin A., Vaz Pato M. V., Tomasz A. A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone. Antimicrob Agents Chemother. 1992 Apr;36(4):886–889. doi: 10.1128/aac.36.4.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Friedland I. R., Shelton S., Paris M., Rinderknecht S., Ehrett S., Krisher K., McCracken G. H., Jr Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J. 1993 Mar;12(3):196–200. doi: 10.1097/00006454-199303000-00004. [DOI] [PubMed] [Google Scholar]
  14. John C. C. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis. 1994 Feb;18(2):188–193. doi: 10.1093/clinids/18.2.188. [DOI] [PubMed] [Google Scholar]
  15. Klugman K. P., Friedland I. R. Antibiotic-resistant pneumococci in pediatric disease. Microb Drug Resist. 1995 Spring;1(1):5–8. doi: 10.1089/mdr.1995.1.5. [DOI] [PubMed] [Google Scholar]
  16. Knudsen J. D., Frimodt-Møller N., Espersen F. Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrob Agents Chemother. 1995 Jun;39(6):1253–1258. doi: 10.1128/aac.39.6.1253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Krause P. J., Owens N. J., Nightingale C. H., Klimek J. J., Lehmann W. B., Quintiliani R. Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serous otitis media. J Infect Dis. 1982 Jun;145(6):815–821. doi: 10.1093/infdis/145.6.815. [DOI] [PubMed] [Google Scholar]
  18. McCracken G. H., Jr, Sakata Y. Antimicrobial therapy of experimental meningitis caused by Streptococcus pneumoniae strains with different susceptibilities to penicillin. Antimicrob Agents Chemother. 1985 Feb;27(2):141–145. doi: 10.1128/aac.27.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nolan C. M., Chalhub E. G., Nash D. G., Yamauchi T. Treatment of bacterial meningitis with intravenous amoxicillin. Antimicrob Agents Chemother. 1979 Aug;16(2):171–175. doi: 10.1128/aac.16.2.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pallares R., Gudiol F., Liñares J., Ariza J., Rufi G., Murgui L., Dorca J., Viladrich P. F. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med. 1987 Jul 2;317(1):18–22. doi: 10.1056/NEJM198707023170104. [DOI] [PubMed] [Google Scholar]
  21. Pallares R., Liñares J., Vadillo M., Cabellos C., Manresa F., Viladrich P. F., Martin R., Gudiol F. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995 Aug 24;333(8):474–480. doi: 10.1056/NEJM199508243330802. [DOI] [PubMed] [Google Scholar]
  22. Portier H., Tremeaux J. C., Chavanet P., Gouyon J. B., Duez J. M., Kazmierczak A. Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination. J Antimicrob Chemother. 1984 Sep;14 (Suppl B):277–284. doi: 10.1093/jac/14.suppl_b.277. [DOI] [PubMed] [Google Scholar]
  23. Sicilia T., Estévez E., Rodríguez A. Fosfomycin penetration into the cerebrospinal fluid of patients with bacterial meningitis. Chemotherapy. 1981;27(6):405–413. doi: 10.1159/000238009. [DOI] [PubMed] [Google Scholar]
  24. Sloas M. M., Barrett F. F., Chesney P. J., English B. K., Hill B. C., Tenover F. C., Leggiadro R. J. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J. 1992 Aug;11(8):662–666. [PubMed] [Google Scholar]
  25. Viladrich P. F., Gudiol F., Liñares J., Rufi G., Ariza J., Pallares R. Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci. Am J Med. 1988 May;84(5):839–846. doi: 10.1016/0002-9343(88)90061-7. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES